Evidence map›Paper›PMID 37577376›Full record

ArticleFrontiers in cellular and infection microbiology2023

Nipah virus attachment glycoprotein ectodomain delivered by type 5 adenovirus vector elicits broad immune response against NiV and HeV.

Xiaoyan Huang, Yaohui Li, Ruihua Li, Shaoyan Wang, Lu Yang, Shuyi Wang, Ying Yin, Xiaodong Zai, Jun Zhang, Junjie Xu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Xiaoyan HuangLaboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing, China.
Yaohui LiLaboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing, China.
Ruihua LiLaboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing, China.
Shaoyan WangLaboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing, China.
Lu YangLaboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing, China.
Shuyi WangLaboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing, China.
Ying YinLaboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing, China.
Xiaodong ZaiLaboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing, China.
Jun ZhangLaboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing, China.
Junjie XuLaboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing, China.
National Vaccine and Serum Institute · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nipah virus (NiV) and Hendra virus (HeV) are newly emerging dangerous zoonotic pathogens of the

Indexed as

Hendra VirusNipah VirusAdenoviridaeAnimalsGlycoproteinsHumansImmunity, CellularMiceVaccines, SyntheticVirus AttachmentGlycoproteinsVaccines, Syntheticadenovirus vectorattachment glycoproteinHendra virusNipah virusT-cell epitopevaccine

Identifiers

PMID37577376
PMCPMC10413271
OpenAlexW4385303029

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.